[In vitro production of red blood cells for future transfusion medicine]

Rinsho Ketsueki. 2023;64(6):482-488. doi: 10.11406/rinketsu.64.482.
[Article in Japanese]

Abstract

Large-scale in vitro red blood cell (RBC) production has been attempted in recent years. Potential cell sources for RBC production include hematopoietic stem/progenitor cells, pluripotent stem cells, and immortalized erythroid progenitor cell lines, which can induce enucleated RBCs with characteristics such as oxygen-carrying capacity and deformability. A phase I clinical study of cultured RBCs produced from hematopoietic stem/progenitor cells has revealed a similar in vivo half-life between cultured and native RBCs. Thus, the application of cultured RBCs in blood transfusion is gradually advancing. However, a single transfusion requires a large number of cells, unlike other cell therapies. Therefore, developing a method to mass-produce RBCs from a small culture volume at a low cost is important in the future. This review summarizes the current status and prospects concerning in vitro RBC production using each cell source, which can improve future transfusion medicine.

Keywords: Hematopoietic stem/progenitor cells; Immortalized erythroid progenitor cells; Pluripotent stem cells; Red blood cells.

Publication types

  • Review
  • English Abstract

MeSH terms

  • Cell Differentiation
  • Erythrocytes
  • Erythroid Precursor Cells / metabolism
  • Erythropoiesis
  • Hematopoietic Stem Cells / metabolism
  • Humans
  • Transfusion Medicine*